Non-specific accumulation of glycosphingolipids in GNE myopathy
Background UDP-GlcNAc 2-epimerase/ManNAc 6-kinase (GNE) is a bifunctional enzyme responsible for the first committed steps in the synthesis of sialic acid, a common terminal monosaccharide in both protein and lipid glycosylation. GNE mutations are responsible for a rare autosomal recessive neuromusc...
Saved in:
Published in | Journal of inherited metabolic disease Vol. 37; no. 2; pp. 297 - 308 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Dordrecht
Springer Netherlands
01.03.2014
Blackwell Publishing Ltd Springer Verlag |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
UDP-GlcNAc 2-epimerase/ManNAc 6-kinase (GNE) is a bifunctional enzyme responsible for the first committed steps in the synthesis of sialic acid, a common terminal monosaccharide in both protein and lipid glycosylation. GNE mutations are responsible for a rare autosomal recessive neuromuscular disorder, GNE myopathy (also called hereditary inclusion body myopathy). The connection between the impairment of sialic acid synthesis and muscle pathology in GNE myopathy remains poorly understood.
Methods
Glycosphingolipid (GSL) analysis was performed by HPLC in multiple models of GNE myopathy, including patients’ fibroblasts and plasma, control fibroblasts with inhibited GNE epimerase activity through a novel imino sugar, and tissues of Gne
M712T/M712T
knock-in mice.
Results
Not only neutral GSLs, but also sialylated GSLs, were significantly increased compared to controls in all tested models of GNE myopathy. Treatment of GNE myopathy fibroblasts with N-acetylmannosamine (ManNAc), a sialic acid precursor downstream of GNE epimerase activity, ameliorated the increased total GSL concentrations.
Conclusion
GNE myopathy models have increased total GSL concentrations. ManNAc supplementation results in decrease of GSL levels, linking abnormal increase of total GSLs in GNE myopathy to defects in the sialic acid biosynthetic pathway. These data advocate for further exploring GSL concentrations as an informative biomarker, not only for GNE myopathy, but also for other disorders of sialic acid metabolism. |
---|---|
Bibliography: | Communicated by: Eva Morava Electronic Supplementary Material The online version of this article (doi:10.1007/s10545‐013‐9655‐6) contains supplementary material, which is available to authorized users. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 PMCID: PMC3979983 Final approval of manuscript: KAP, TY, ELP-C, DSA, NVK, PL, HD, BX, YZ, MS, YB, WAG, MH, TDB Conception and design: KAP, TY, DSA, NVK, YB, MH, TDB Acquisition of data: KAP, TY, ELP-C, DSA, NVK, PL, HD, BX, MS Author Contributions Analysis and interpretation of data: KAP, TY, DSA, NVK, PL, HD, WAG, MH, TDB Drafting/revising and final approval of manuscript: KAP, TY, ELP-C, DSA, NVK, BX, YZ, MS, YB, WAG, MH, TDB |
ISSN: | 0141-8955 1573-2665 |
DOI: | 10.1007/s10545-013-9655-6 |